Our finding that ODF2L was a synthetic lethal partner with WEE1 and that loss of ODF2L sensitized the response to WEE1 inhibitors in ovarian cancer indicated that ODF2L could be a promising translational target for ovarian cancer treatment. This evidence concerns the gene WEE1 and ovarian carcinoma.